These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
184 related articles for article (PubMed ID: 31999671)
1. In brief: Tafamidis (Vyndaqel; Vyndamax) for transthyretin amyloid cardiomyopathy. Med Lett Drugs Ther; 2020 Jan; 62(1590):16. PubMed ID: 31999671 [No Abstract] [Full Text] [Related]
2. Tafamidis: A First-in-Class Transthyretin Stabilizer for Transthyretin Amyloid Cardiomyopathy. Park J; Egolum U; Parker S; Andrews E; Ombengi D; Ling H Ann Pharmacother; 2020 May; 54(5):470-477. PubMed ID: 31735059 [No Abstract] [Full Text] [Related]
3. Tafamidis: A Review in Transthyretin Amyloid Cardiomyopathy. Lamb YN Am J Cardiovasc Drugs; 2021 Jan; 21(1):113-121. PubMed ID: 33469827 [TBL] [Abstract][Full Text] [Related]
4. Tafamidis for transthyretin amyloid cardiomyopathy: the solution or just the beginning of the end? Falk RH Eur Heart J; 2019 Mar; 40(12):1009-1012. PubMed ID: 30668704 [No Abstract] [Full Text] [Related]
8. Tafamidis in the Treatment of ATTR-related Cardiomyopathy: Indications and Grey Zones. Capovilla TM; Lalario A; Rossi M; Porcari A; Aimo A; Limongelli G; Emdin M; Merlo M; Sinagra G Heart Fail Clin; 2024 Jul; 20(3):333-341. PubMed ID: 38844304 [TBL] [Abstract][Full Text] [Related]
9. Estimating the annual economic burden for the management of patients with transthyretin amyloid polyneuropathy in Spain. Galan L; Gonzalez-Moreno J; Martínez-Sesmero JM; Muñoz-Beamud F; Santos-Rubio MD; Tran D; Lebeau P; Stewart M; Mallaina P; Tarilonte P; Peral C; Rozenbaum MH Expert Rev Pharmacoecon Outcomes Res; 2021 Oct; 21(5):967-973. PubMed ID: 33724140 [No Abstract] [Full Text] [Related]
10. Longitudinal evolution of ventricular function and cardiac magnetic resonance imaging tissue characteristics in tafamidis-treated transthyretin amyloid cardiomyopathy. Dobner S; Bernhard B; Wieser M; Wahl A; Stark AW; Köchli V; Spano G; Boscolo Berto M; Johner C; Elchinova E; Tanner G; Safarkhanlo Y; Stortecky S; Schütze J; Hunziker Munsch L; Gräni C Amyloid; 2024 Jun; 31(2):145-147. PubMed ID: 38069637 [No Abstract] [Full Text] [Related]
11. The Bioequivalence of Tafamidis 61-mg Free Acid Capsules and Tafamidis Meglumine 4 × 20-mg Capsules in Healthy Volunteers. Lockwood PA; Le VH; O'Gorman MT; Patterson TA; Sultan MB; Tankisheva E; Wang Q; Riley S Clin Pharmacol Drug Dev; 2020 Oct; 9(7):849-854. PubMed ID: 32196976 [TBL] [Abstract][Full Text] [Related]
12. Tafamidis (Vyndaqel): a light for FAP patients. Nencetti S; Rossello A; Orlandini E ChemMedChem; 2013 Oct; 8(10):1617-9. PubMed ID: 24000164 [TBL] [Abstract][Full Text] [Related]
13. Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy. Maurer MS; Schwartz JH; Gundapaneni B; Elliott PM; Merlini G; Waddington-Cruz M; Kristen AV; Grogan M; Witteles R; Damy T; Drachman BM; Shah SJ; Hanna M; Judge DP; Barsdorf AI; Huber P; Patterson TA; Riley S; Schumacher J; Stewart M; Sultan MB; Rapezzi C; N Engl J Med; 2018 Sep; 379(11):1007-1016. PubMed ID: 30145929 [TBL] [Abstract][Full Text] [Related]
14. Specific Therapy in Transthyretin Amyloid Cardiomyopathy: Future Perspectives Beyond Tafamidis. Saro R; Allegro V; Merlo M; Dore F; Sinagra G; Porcari A Heart Fail Clin; 2024 Jul; 20(3):343-352. PubMed ID: 38844305 [TBL] [Abstract][Full Text] [Related]
15. [What gnaws at the heart and gets on the nerves]. Kristen AV Internist (Berl); 2018 Nov; 59(11):1208-1213. PubMed ID: 30039176 [TBL] [Abstract][Full Text] [Related]
16. A Statement on the Appropriate Administration of Tafamidis in Patients With Transthyretin Cardiac Amyloidosis. Endo J; Sano M; Izumiya Y; Tsujita K; Nakamura K; Tahara N; Kuwahara K; Inomata T; Ueda M; Sekijima Y; Ando Y; Tsutsui H; Isobe M; Fukuda K Circ J; 2019 Dec; 84(1):15-17. PubMed ID: 31735731 [TBL] [Abstract][Full Text] [Related]
17. Causes of Cardiovascular Hospitalization and Death in Patients With Transthyretin Amyloid Cardiomyopathy (from the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial [ATTR-ACT]). Miller AB; Januzzi JL; O'Neill BJ; Gundapaneni B; Patterson TA; Sultan MB; López-Sendón J Am J Cardiol; 2021 Jun; 148():146-150. PubMed ID: 33667442 [TBL] [Abstract][Full Text] [Related]
18. Cardiac Biomarker Change at 1 Year After Tafamidis Treatment and Clinical Outcomes in Patients With Transthyretin Amyloid Cardiomyopathy. Kuyama N; Takashio S; Oguni T; Yamamoto M; Hirakawa K; Ishii M; Hanatani S; Oda S; Matsuzawa Y; Usuku H; Yamamoto E; Hirai T; Ueda M; Tsujita K J Am Heart Assoc; 2024 May; 13(10):e034518. PubMed ID: 38761073 [TBL] [Abstract][Full Text] [Related]
19. Efficacy of Tafamidis in Patients With Hereditary and Wild-Type Transthyretin Amyloid Cardiomyopathy: Further Analyses From ATTR-ACT. Rapezzi C; Elliott P; Damy T; Nativi-Nicolau J; Berk JL; Velazquez EJ; Boman K; Gundapaneni B; Patterson TA; Schwartz JH; Sultan MB; Maurer MS JACC Heart Fail; 2021 Feb; 9(2):115-123. PubMed ID: 33309574 [TBL] [Abstract][Full Text] [Related]
20. Personalized medicine approach for optimizing the dose of tafamidis to potentially ameliorate wild-type transthyretin amyloidosis (cardiomyopathy). Cho Y; Baranczak A; Helmke S; Teruya S; Horn EM; Maurer MS; Kelly JW Amyloid; 2015; 22(3):175-80. PubMed ID: 26193961 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]